Quote from: AnonyMs on September 11, 2016, 08:56:14 PM
I've not made the effort to read that paper properly, but I'm not confident its very credible. The sample sizes are tiny and one of the estrogen's they use is Ethinyl Estradiol. Also its out of the Netherlands, and I've seen some really poor trans related papers from there.
That was one of the points of the paper. Cyproterone acetate (CPA)-only, transdermal estradiol (E2) + CPA, oral E2 +CPA, and oral ethanol estradiol (EE) were compared. Only oral EE resulted in a large increase in activated protein C (APC) resistance.
There was an increased risk of blood clots associated with oral estradiol (E2), but not transdermal E2, and more pronounced risk associated with oral ethinyl estradiol (EE), or oral E2 plus progestins (such as in birth control pills, or HRT using oral EE or E2 plus cyproterone acetate, CPA) or CPA alone.
I have posted this elsewhere, but again, these results are consistent with other studies on cis-women:
"Our data show that oral, unlike transdermal, estrogen induces APC resistance and activates blood coagulation. These results emphasize the importance of the route of estrogen administration".
Differential Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Sensitivity to Activated Protein C Among Postmenopausal Women
Arteriosclerosis, Thrombosis, and Vascular Biology 23:1671-1676 (2003)
The sample size was 30 MtF and the correlations were highly significant (P <0.005). I don't know what you find questionable about it, but you're certainly entitled to your opinion.
~Terri